## Rafael Maldonado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4483214/publications.pdf Version: 2024-02-01

		6613	10445
341	24,310	79	139
papers	citations	h-index	g-index
362	362	362	17183
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders. British Journal of Pharmacology, 2023, 180, 879-893.	5.4	7
2	Functional protection in J20/VLW mice: a model of non-demented with Alzheimer's disease neuropathology. Brain, 2022, 145, 729-743.	7.6	2
3	Cell-type- and region-specific modulation of cocaine seeking by micro-RNA-1 in striatal projection neurons. Molecular Psychiatry, 2022, 27, 918-928.	7.9	6
4	Operant Self-medication for Assessment of Spontaneous Pain Relief and Drug Abuse Liability in Mouse Models of Chronic Pain. Bio-protocol, 2022, 12, e4348.	0.4	0
5	miRNA signatures associated with vulnerability to food addiction in mice and humans. Journal of Clinical Investigation, 2022, 132, .	8.2	10
6	Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Cell Host and Microbe, 2022, 30, 340-356.e8.	11.0	50
7	COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing. Vaccines, 2022, 10, 594.	4.4	4
8	Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomedicine and Pharmacotherapy, 2022, 149, 112925.	5.6	11
9	Microbiota alterations in proline metabolism impact depression. Cell Metabolism, 2022, 34, 681-701.e10.	16.2	77
10	Presence of <i>Blastocystis</i> in gut microbiota is associated with cognitive traits and decreased executive function. ISME Journal, 2022, 16, 2181-2197.	9.8	10
11	Differential expression of miRâ€1249â€3p and miRâ€34bâ€5p between vulnerable and resilient phenotypes of cocaine addiction. Addiction Biology, 2022, 27, .	2.6	7
12	Protein Kinase C-Gamma Knockout Mice Show Impaired Hippocampal Short-Term Memory While Preserved Long-Term Memory. Molecular Neurobiology, 2021, 58, 617-630.	4.0	14
13	Behavioral sensitization and cellular responses to psychostimulants are reduced in D2R knockout mice. Addiction Biology, 2021, 26, e12840.	2.6	14
14	Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons drives overconsumption of palatable food and obesity. Neuropsychopharmacology, 2021, 46, 982-991.	5.4	3
15	Role of the endocannabinoid system in a mouse model of Fragile X undergoing neuropathic pain. European Journal of Pain, 2021, 25, 1316-1328.	2.8	7
16	Daidzein modulates cocaine-reinforcing effects and cue-induced cocaine reinstatement in CD-1 male mice. Psychopharmacology, 2021, 238, 1923-1936.	3.1	1
17	Transcriptional signatures in prefrontal cortex confer vulnerability versus resilience to food and cocaine addiction-like behavior. Scientific Reports, 2021, 11, 9076.	3.3	17
18	Genomics and epigenomics of addiction. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 128-139.	1.7	13

#	Article	IF	CITATIONS
19	Orally Active Peptide Vector Allows Using Cannabis to Fight Pain While Avoiding Side Effects. Journal of Medicinal Chemistry, 2021, 64, 6937-6948.	6.4	9
20	Accidental Interruption of the Cold Chain for the Preservation of the Moderna COVID-19 Vaccine. Vaccines, 2021, 9, 512.	4.4	5
21	Synergism between oral paracetamol and nefopam in a murine model of postoperative pain. European Journal of Pain, 2021, 25, 1770-1787.	2.8	4
22	Reconstituted mRNA COVID-19 vaccines may maintain stability after continuous movement. Clinical Microbiology and Infection, 2021, 27, 1698.e1-1698.e4.	6.0	6
23	Kappa opioid receptor modulation of endometriosis pain in mice. Neuropharmacology, 2021, 195, 108677.	4.1	10
24	Delta Opioid Receptor in Astrocytes Contributes to Neuropathic Cold Pain and Analgesic Tolerance in Female Mice. Frontiers in Cellular Neuroscience, 2021, 15, 745178.	3.7	7
25	The CB2 cannabinoid receptor as a therapeutic target in the central nervous system. Expert Opinion on Therapeutic Targets, 2021, 25, 659-676.	3.4	11
26	Reduced cue-induced reinstatement of cocaine-seeking behavior in Plcb1 +/â^' mice. Translational Psychiatry, 2021, 11, 521.	4.8	4
27	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. Clinical Nutrition, 2020, 39, 378-387.	5.0	16
28	Mu and delta opioid receptors play opposite nociceptive and behavioural roles on nerveâ€injured mice. British Journal of Pharmacology, 2020, 177, 1187-1205.	5.4	14
29	THC exposure during adolescence does not modify nicotine reinforcing effects and relapse in adult male mice. Psychopharmacology, 2020, 237, 801-809.	3.1	9
30	Obesity Impairs Short-Term and Working Memory through Gut Microbial Metabolism of Aromatic Amino Acids. Cell Metabolism, 2020, 32, 548-560.e7.	16.2	88
31	Early 5― <scp>HT</scp> <sub>6</sub> receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Molecular Medicine, 2020, 12, e10605.	6.9	18
32	A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction. Nature Communications, 2020, 11, 782.	12.8	70
33	Auricular transcutaneous vagus nerve stimulation improves memory persistence in naÃ <sup>-</sup> ve mice and in an intellectual disability mouse model. Brain Stimulation, 2020, 13, 494-498.	1.6	25
34	Surgical Induction of Endometriosis in Female Mice. Bio-protocol, 2020, 10, e3763.	0.4	4
35	The endocannabinoid system in modulating fear, anxiety, and stress. Dialogues in Clinical Neuroscience, 2020, 22, 229-239.	3.7	30
36	Disease-modifying effects of natural Δ9-tetrahydrocannabinol in endometriosis-associated pain. ELife, 2020, 9, .	6.0	20

#	Article	IF	CITATIONS
37	Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain. ELife, 2020, 9, .	6.0	36
38	An Operant Conditioning Model Combined with a Chemogenetic Approach to Study the Neurobiology of Food Addiction in Mice. Bio-protocol, 2020, 10, e3777.	0.4	3
39	An Alternative Maze to Assess Novel Object Recognition in Mice. Bio-protocol, 2020, 10, e3651.	0.4	7
40	Cerebral oxidative metabolism mapping in four genetic mouse models of anxiety and mood disorders. Behavioural Brain Research, 2019, 356, 435-443.	2.2	6
41	Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in <i>Mbnl2</i> Knockout Mice and Reduces Microglia Overexpression. Cerebral Cortex, 2019, 29, 2978-2997.	2.9	20
42	Sigmaâ€l receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain. British Journal of Pharmacology, 2019, 176, 3939-3955.	5.4	26
43	Monoacylglycerol lipase blockade impairs fine motor coordination and triggers cerebellar neuroinflammation through cyclooxygenase-2. Brain, Behavior, and Immunity, 2019, 81, 399-409.	4.1	11
44	Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome. Neurobiology of Disease, 2019, 125, 92-106.	4.4	26
45	Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain. Frontiers in Pharmacology, 2019, 10, 468.	3.5	29
46	Anti-inflammatory agents for smoking cessation? Focus on cognitive deficits associated with nicotine withdrawal in male mice. Brain, Behavior, and Immunity, 2019, 75, 228-239.	4.1	28
47	Concomitant THC and stress adolescent exposure induces impaired fear extinction and related neurobiological changes in adulthood. Neuropharmacology, 2019, 144, 345-357.	4.1	30
48	Why muâ€opioid agonists have less analgesic efficacy in neuropathic pain?. European Journal of Pain, 2019, 23, 435-454.	2.8	45
49	Use of the Vsoc-maze to Study Sociability and Preference for Social Novelty in Rodents. Bio-protocol, 2019, 9, e3393.	0.4	2
50	Increased Alcohol Seeking in Mice Lacking Gpr88 Involves Dysfunctional Mesocorticolimbic Networks. Biological Psychiatry, 2018, 84, 202-212.	1.3	41
51	Extinction and reinstatement of an operant responding maintained by food in different models of obesity. Addiction Biology, 2018, 23, 544-555.	2.6	11
52	Timeâ€course and dynamics of obesityâ€related behavioral changes induced by energyâ€dense foods in mice. Addiction Biology, 2018, 23, 531-543.	2.6	13
53	Red Bull® energy drink increases consumption of higher concentrations of alcohol. Addiction Biology, 2018, 23, 1094-1105.	2.6	17
54	Cafeteria diet induces neuroplastic modifications in the nucleus accumbens mediated by microglia activation. Addiction Biology, 2018, 23, 735-749.	2.6	30

#	Article	IF	CITATIONS
55	Hippocampal Protein Kinase C Signaling Mediates the Short-Term Memory Impairment Induced by Delta9-Tetrahydrocannabinol. Neuropsychopharmacology, 2018, 43, 1021-1031.	5.4	21
56	Usefulness of knockout mice to clarify the role of the opioid system in chronic pain. British Journal of Pharmacology, 2018, 175, 2791-2808.	5.4	31
57	Role of the endocannabinoid system in drug addiction. Biochemical Pharmacology, 2018, 157, 108-121.	4.4	87
58	Octadecylpropyl Sulfamide Reduces Neurodegeneration and Restores the Memory Deficits Induced by Hypoxia-Ischemia in Mice. Frontiers in Pharmacology, 2018, 9, 376.	3.5	10
59	Effects of repeated social defeat on adolescent mice on cocaineâ€induced CPP and selfâ€administration in adulthood: integrity of the blood–brain barrier. Addiction Biology, 2017, 22, 129-141.	2.6	62
60	Role of DOR in neuronal plasticity changes promoted by food-seeking behaviour. Addiction Biology, 2017, 22, 1179-1190.	2.6	7
61	Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. Expert Review of Clinical Pharmacology, 2017, 10, 443-455.	3.1	66
62	Facilitation of Contextual Fear Extinction by Orexin-1 Receptor Antagonism Is Associated with the Activation of Specific Amygdala Cell Subpopulations. International Journal of Neuropsychopharmacology, 2017, 20, 654-659.	2.1	34
63	Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food. Biological Psychiatry, 2017, 81, 778-788.	1.3	53
64	Serotonin 2B Receptors in Mesoaccumbens Dopamine Pathway Regulate Cocaine Responses. Journal of Neuroscience, 2017, 37, 10372-10388.	3.6	34
65	CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. Biological Psychiatry, 2017, 81, 625-634.	1.3	24
66	Involvement of the dynorphin/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice. Neuropharmacology, 2017, 116, 315-327.	4.1	36
67	The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology, 2017, 114, 156-167.	4.1	64
68	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	3.7	101
69	Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model. Genes, 2016, 7, 56.	2.4	39
70	Nalmefene is effective at reducing alcohol seeking, treating alcoholâ€cocaine interactions and reducing alcoholâ€induced histone deacetylases gene expression in blood. British Journal of Pharmacology, 2016, 173, 2490-2505.	5.4	17
71	Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ <sup>9</sup> â€tetrahydrocannabinol. British Journal of Pharmacology, 2016, 173, 1381-1392. 	5.4	18
72	Effects of pregabalin on the nociceptive, emotional and cognitive manifestations of neuropathic pain in mice. European Journal of Pain, 2016, 20, 1454-1466.	2.8	34

#	Article	IF	CITATIONS
73	Morphine-induced locomotor sensitization produces structural plasticity in the mesocorticolimbic system dependent on CB1-R activity. Addiction Biology, 2016, 21, 1113-1126.	2.6	22
74	CB2 cannabinoid receptors modulate HIF-1α and TIM-3 expression in a hypoxia-ischemia mouse model. European Neuropsychopharmacology, 2016, 26, 1972-1988.	0.7	23
75	Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine. Journal of Alzheimer's Disease, 2016, 51, 489-500.	2.6	56
76	Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9904-9909.	7.1	63
77	Ephrinâ€82 prevents Nâ€methylâ€Dâ€aspartate receptor antibody effects on memory and neuroplasticity. Annals of Neurology, 2016, 80, 388-400.	5.3	134
78	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain, Behavior, and Immunity, 2016, 57, 94-105.	4.1	51
79	The endocannabinoid system and neuropathic pain. Pain, 2016, 157, S23-S32.	4.2	72
80	Epigenetics, behavior and early nicotine. Nature Neuroscience, 2016, 19, 863-864.	14.8	2
81	Differential Control of Cocaine Self-Administration by GABAergic and Glutamatergic CB1 Cannabinoid Receptors. Neuropsychopharmacology, 2016, 41, 2192-2205.	5.4	43
82	Role of β4* Nicotinic Acetylcholine Receptors in the Habenulo–Interpeduncular Pathway in Nicotine Reinforcement in Mice. Neuropsychopharmacology, 2016, 41, 1790-1802.	5.4	30
83	Glutamatergic stimulation induces GluN2B translation by the nitric oxide-Heme-Regulated elF2α kinase in cortical neurons. Oncotarget, 2016, 7, 58876-58892.	1.8	14
84	Longâ€lasting oral analgesic effects of <i>N</i> â€protected aminophosphinic dual <scp>ENK</scp> ephalinase inhibitors ( <scp>DENKI</scp> s) in peripherally controlled pain. Pharmacology Research and Perspectives, 2015, 3, e00116.	2.4	21
85	Frustrated expected reward induces differential transcriptional changes in the mouse brain. Addiction Biology, 2015, 20, 22-37.	2.6	12
86	Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain. Pain, 2015, 156, 2001-2012.	4.2	71
87	Differential regulation of <scp>mGlu<sub>5</sub>R</scp> and <scp>ΜOPr</scp> by priming―and cueâ€induced reinstatement of cocaineâ€seeking behaviour in mice. Addiction Biology, 2015, 20, 902-912.	2.6	31
88	Epigenetic and Proteomic Expression Changes Promoted by Eating Addictive-Like Behavior. Neuropsychopharmacology, 2015, 40, 2788-2800.	5.4	44
89	Physiological Control of Nitric Oxide in Neuronal <i>BACE1</i> Translation by Heme-Regulated eIF2α Kinase HRI Induces Synaptogenesis. Antioxidants and Redox Signaling, 2015, 22, 1295-1307.	5.4	26
90	Orexins and fear: implications for the treatment of anxiety disorders. Trends in Neurosciences, 2015, 38, 550-559.	8.6	83

6

#	Article	IF	CITATIONS
91	The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. Molecular Psychiatry, 2015, 20, 1448-1459.	7.9	59
92	Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans. Alcoholism: Clinical and Experimental Research, 2015, 39, 1939-1950.	2.4	31
93	5-HT2C Receptor Desensitization Moderates Anxiety in 5-HTT Deficient Mice: From Behavioral to Cellular Evidence. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	13
94	The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 2015, 16, 705-718.	10.2	350
95	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain, 2015, 138, 94-109.	7.6	391
96	A Novel Anxiogenic Role for the Delta Opioid Receptor Expressed in GABAergic Forebrain Neurons. Biological Psychiatry, 2015, 77, 404-415.	1.3	31
97	Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLoS Biology, 2015, 13, e1002194.	5.6	157
98	DREAM Controls the On/Off Switch of Specific Activity-Dependent Transcription Pathways. Molecular and Cellular Biology, 2014, 34, 877-887.	2.3	41
99	The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. International Journal of Neuropsychopharmacology, 2014, 17, 455-468.	2.1	37
100	The α3β4* nicotinic <scp>ACh</scp> receptor subtype mediates physical dependence to morphine: mouse and human studies. British Journal of Pharmacology, 2014, 171, 3845-3857.	5.4	34
101	Relationships between serotonergic and cannabinoid system in depressiveâ€like behavior: a <scp>PET</scp> study with [ <sup>11</sup> C]â€ <scp>DASB</scp> . Journal of Neurochemistry, 2014, 130, 126-135.	3.9	31
102	Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology, 2014, 231, 3031-3040.	3.1	23
103	Involvement of the endocannabinoid system in osteoarthritis pain. European Journal of Neuroscience, 2014, 39, 485-500.	2.6	41
104	Pregnenolone Can Protect the Brain from Cannabis Intoxication. Science, 2014, 343, 94-98.	12.6	247
105	Human N-methyl-d-aspartate receptor antibodies alter memory and behavior in a passive ventricular murine infusion model. Journal of Neuroimmunology, 2014, 275, 119.	2.3	0
106	Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice. European Neuropsychopharmacology, 2014, 24, 1773-1783.	0.7	13
107	Cannabis-Based Medicine Reduces Multiple Pathological Processes in AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2014, 43, 977-991.	2.6	110
108	Effects of Genetic Deletion of Endogenous Opioid System Components on the Reinstatement of Cocaine-Seeking Behavior in Mice. Neuropsychopharmacology, 2014, 39, 2974-2988.	5.4	32

#	Article	IF	CITATIONS
109	Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. Nature Communications, 2014, 5, 3443.	12.8	108
110	New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model. International Journal of Biochemistry and Cell Biology, 2014, 53, 121-126.	2.8	25
111	The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward. Biological Psychiatry, 2014, 75, 499-507.	1.3	38
112	The Hypocretin/Orexin System Mediates the Extinction of Fear Memories. Neuropsychopharmacology, 2014, 39, 2732-2741.	5.4	112
113	Baclofen and 2-hydroxysaclofen modify acute hypolocomotive and antinociceptive effects of nicotine. European Journal of Pharmacology, 2014, 738, 200-205.	3.5	8
114	Genetically Modified Mice as Tools to Understand the Neurobiological Substrates of Depression. Current Pharmaceutical Design, 2014, 20, 3718-3737.	1.9	2
115	Effects of repeated treatment with MDMA on working memory and behavioural flexibility in mice. Addiction Biology, 2013, 18, 263-273.	2.6	31
116	Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nature Medicine, 2013, 19, 603-607.	30.7	203
117	Endocannabinoid system and drug addiction: new insights from mutant mice approaches. Current Opinion in Neurobiology, 2013, 23, 480-486.	4.2	15
118	CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2013, 35, 847-858.	2.6	167
119	A Role for Hypocretin/Orexin Receptor-1 in Cue-Induced Reinstatement of Nicotine-Seeking Behavior. Neuropsychopharmacology, 2013, 38, 1724-1736.	5.4	62
120	Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology, 2013, 73, 388-396.	4.1	111
121	Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. Pain, 2013, 154, 160-174.	4.2	66
122	An investigation of interactions between hypocretin/orexin signaling and glutamate receptor surface expression in the rat nucleus accumbens under basal conditions and after cocaine exposure. Neuroscience Letters, 2013, 557, 101-106.	2.1	8
123	Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. Journal of Neuroimmunology, 2013, 261, 53-59.	2.3	42
124	Operant behavior to obtain palatable food modifies ERK activity in the brain reward circuit. European Neuropsychopharmacology, 2013, 23, 240-252.	0.7	20
125	Dissociation of the Pharmacological Effects of THC by mTOR Blockade. Neuropsychopharmacology, 2013, 38, 1334-1343.	5.4	75
126	Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1001-1014.	3.3	43

#	Article	IF	CITATIONS
127	Operant behavior to obtain palatable food modifies neuronal plasticity in the brain reward circuit. European Neuropsychopharmacology, 2013, 23, 146-159.	0.7	41
128	Involvement of the opioid and cannabinoid systems in pain control: New insights from knockout studies. European Journal of Pharmacology, 2013, 716, 142-157.	3.5	48
129	Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects. European Journal of Pharmacology, 2013, 711, 63-72.	3.5	76
130	Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine. Neuropsychopharmacology, 2013, 38, 2515-2524.	5.4	109
131	Operant selfâ€administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain. European Journal of Pain, 2013, 17, 832-843.	2.8	34
132	Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Frontiers in Neuroscience, 2013, 7, 256.	2.8	55
133	Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. Journal of Clinical Investigation, 2013, 123, 2816-2831.	8.2	101
134	Sex-Dependent Psychoneuroendocrine Effects of THC and MDMA in an Animal Model of Adolescent Drug Consumption. PLoS ONE, 2013, 8, e78386.	2.5	30
135	Decreased Cocaine Motor Sensitization and Self-Administration in Mice Overexpressing Cannabinoid CB2 Receptors. Neuropsychopharmacology, 2012, 37, 1749-1763.	5.4	104
136	Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3254-3263.	4.0	82
137	Selective re-expression of $\hat{l}^22$ nicotinic acetylcholine receptor subunits in the ventral tegmental area of the mouse restores intravenous nicotine self-administration. Neuropharmacology, 2012, 63, 235-241.	4.1	22
138	Pharmacological properties of S1RA, a new sigmaâ€₁ receptor antagonist that inhibits neuropathic pain and activityâ€induced spinal sensitization. British Journal of Pharmacology, 2012, 166, 2289-2306.	5.4	159
139	Overexpression of α3/α5/β4 nicotinic receptor subunits modifies impulsive-like behavior. Drug and Alcohol Dependence, 2012, 122, 247-252.	3.2	12
140	Hypocretin/Orexin Signaling in the Hypothalamic Paraventricular Nucleus is Essential for the Expression of Nicotine Withdrawal. Biological Psychiatry, 2012, 71, 214-223.	1.3	77
141	CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2012, 30, 439-459.	2.6	96
142	Influence of δ-Opioid Receptors in the Behavioral Effects of Nicotine. Neuropsychopharmacology, 2012, 37, 2332-2344.	5.4	38
143	The Hypocretin/Orexin System: Implications for Drug Reward and Relapse. Molecular Neurobiology, 2012, 45, 424-439.	4.0	47
144	Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino Acids, 2012, 43, 897-909.	2.7	36

#	Article	IF	CITATIONS
145	Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. British Journal of Pharmacology, 2012, 165, 424-435.	5.4	64
146	Operant model of frustrated expected reward in mice. Addiction Biology, 2012, 17, 770-782.	2.6	42
147	Active and passive MDMA (â€~ecstasy') intake induces differential transcriptional changes in the mouse brain. Genes, Brain and Behavior, 2012, 11, 38-51.	2.2	20
148	Deletion of the δOpioid Receptor Gene Impairs Place Conditioning But Preserves Morphine Reinforcement. Biological Psychiatry, 2011, 69, 700-703.	1.3	67
149	Differential Role of Anandamide and 2-Arachidonoylglycerol in Memory and Anxiety-like Responses. Biological Psychiatry, 2011, 70, 479-486.	1.3	248
150	Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour. International Journal of Neuropsychopharmacology, 2011, 14, 927-940.	2.1	36
151	Altered expression of neuronal tryptophan hydroxylase-2 mRNA in the dorsal and median raphe nuclei of three genetically modified mouse models relevant to depression and anxiety. Journal of Chemical Neuroanatomy, 2011, 41, 227-233.	2.1	13
152	Neurochemical basis of cannabis addiction. Neuroscience, 2011, 181, 1-17.	2.3	93
153	Genes differentially expressed in CB1 knockout mice: Involvement in the depressive-like phenotype. European Neuropsychopharmacology, 2011, 21, 11-22.	0.7	40
154	Shared changes in gene expression in frontal cortex of four genetically modified mouse models of depression. European Neuropsychopharmacology, 2011, 21, 3-10.	0.7	12
155	Positron Emission Tomographic Imaging of the Cannabinoid Type 1 Receptor System with [11C]OMAR ([11C]JHU75528): Improvements in Image Quantification Using Wild-Type and Knockout Mice. Molecular Imaging, 2011, 10, 7290.2011.00019.	1.4	7
156	Sensitization to MDMA locomotor effects and changes in the functionality of 5-HT2A and D2 receptors in mice. Behavioural Pharmacology, 2011, 22, 362-369.	1.7	15
157	Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain, 2011, 152, 1238-1248.	4.2	139
158	Regulation of the immediate-early genes arc and zif268 in a mouse operant model of cocaine seeking reinstatement. Journal of Neural Transmission, 2011, 118, 877-887.	2.8	19
159	New operant model of reinstatement of food-seeking behavior in mice. Psychopharmacology, 2011, 215, 49-70.	3.1	32
160	Overexpression of Reelin Prevents the Manifestation of Behavioral Phenotypes Related to Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2011, 36, 2395-2405.	5.4	85
161	Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia, 2010, 53, 2629-2640.	6.3	107
162	Effects of repeated MDMA administration on the motivation for palatable food and extinction of operant responding in mice. Psychopharmacology, 2010, 208, 563-573.	3.1	5

#	Article	IF	CITATIONS
163	Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. Pain, 2010, 149, 483-494.	4.2	79
164	Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system. Neuroscience and Biobehavioral Reviews, 2010, 35, 220-231.	6.1	118
165	Essential role of the N-terminal region of TFII-I in viability and behavior. BMC Medical Genetics, 2010, 11, 61.	2.1	35
166	Effects of the endogenous PPARâ€Î± agonist, oleoylethanolamide on MDMAâ€induced cognitive deficits in mice. Synapse, 2010, 64, 379-389.	1.2	42
167	Central and peripheral consequences of the chronic blockade of CB <sub>1</sub> cannabinoid receptor with rimonabant or taranabant. Journal of Neurochemistry, 2010, 112, 1338-13351.	3.9	24
168	Effects of the cell typeâ€specific ablation of the cAMPâ€responsive transcription factor in noradrenergic neurons on locus coeruleus firing and withdrawal behavior after chronic exposure to morphine. Journal of Neurochemistry, 2010, 115, 563-573.	3.9	20
169	5â€HT <sub>2C</sub> receptor activation prevents stressâ€induced enhancement of brain 5â€HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. Journal of Neurochemistry, 2010, 115, 438-449.	3.9	49
170	FAAH deficiency promotes energy storage and enhances the motivation for food. International Journal of Obesity, 2010, 34, 557-568.	3.4	74
171	Differential regionâ€specific regulation of α4β2* nAChRs by selfâ€administered and nonâ€contingent nicotine in C57BL/6J mice. Addiction Biology, 2010, 15, 464-479.	2.6	36
172	Hypocretins Regulate the Anxiogenic-Like Effects of Nicotine and Induce Reinstatement of Nicotine-Seeking Behavior. Journal of Neuroscience, 2010, 30, 2300-2310.	3.6	153
173	The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence, 2010, 108, 183-194.	3.2	198
174	Effects of chronic nicotine on food intake and anxiety-like behaviour in CB1 knockout mice. European Neuropsychopharmacology, 2010, 20, 369-378.	0.7	39
175	Endogenous Cannabinoid and Opioid Systems and their Role in Nicotine Addiction. Current Drug Targets, 2010, 11, 440-449.	2.1	19
176	GPR3 Receptor, a Novel Actor in the Emotional-Like Responses. PLoS ONE, 2009, 4, e4704.	2.5	60
177	Increased opioid dependence in a mouse model of panic disorder. Frontiers in Behavioral Neuroscience, 2009, 3, 60.	2.0	10
178	Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice. Psychopharmacology, 2009, 205, 457-466.	3.1	19
179	Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test. Psychopharmacology, 2009, 205, 475-487.	3.1	21
180	Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nature Neuroscience, 2009, 12, 1152-1158.	14.8	343

#	Article	IF	CITATIONS
181	Attenuated behavioural responses to acute and chronic cocaine in GASPâ€lâ€deficient mice. European Journal of Neuroscience, 2009, 30, 860-868.	2.6	31
182	Lack of CB <sub>1</sub> receptor activity impairs serotonergic negative feedback. Journal of Neurochemistry, 2009, 109, 935-944.	3.9	85
183	Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology, 2009, 56, 653-664.	4.1	63
184	Nicotine anxiogenic and rewarding effects are decreased in mice lacking β-endorphin. Neuropharmacology, 2009, 56, 1147-1153.	4.1	56
185	The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins. Pain, 2009, 141, 88-96.	4.2	47
186	Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain, 2009, 145, 294-303.	4.2	154
187	Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) Controls Activation of Extracellular Signal-Regulated Kinase (ERK) Signaling in the Striatum and Long-Term Behavioral Responses to Cocaine. Biological Psychiatry, 2009, 66, 758-768.	1.3	96
188	MDMA reinstates cocaine-seeking behaviour in mice. European Neuropsychopharmacology, 2009, 19, 391-397.	0.7	12
189	P.2.b.018 Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype. European Neuropsychopharmacology, 2009, 19, S401-S402.	0.7	Ο
190	Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. International Journal of Neuropsychopharmacology, 2009, 12, 615.	2.1	45
191	New operant model of nicotine-seeking behaviour in mice. International Journal of Neuropsychopharmacology, 2009, 12, 343.	2.1	33
192	Selective Sigma-1 (σ1) Receptor Antagonists: Emerging Target for the Treatment of Neuropathic Pain. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 172-183.	1.1	82
193	MDMA modifies active avoidance learning and recall in mice. Psychopharmacology, 2008, 197, 391-400.	3.1	22
194	A reliable method to study cue-, priming-, and stress-induced reinstatement of cocaine self-administration in mice. Psychopharmacology, 2008, 199, 593-603.	3.1	52
195	Behavioural and biochemical responses to morphine associated with its motivational properties are altered in adenosine A <sub>2A</sub> receptor knockout mice. British Journal of Pharmacology, 2008, 155, 757-766.	5.4	22
196	BDNF impairment in the hippocampus is related to enhanced despair behavior in CB <sub>1</sub> knockout mice. Journal of Neurochemistry, 2008, 105, 565-572.	3.9	175
197	Involvement of kappa/dynorphin system in the development of tolerance to nicotine-induced antinociception. Journal of Neurochemistry, 2008, 105, 1358-1368.	3.9	19
198	Advances in the field of cannabinoid–opioid crossâ€ŧalk. Addiction Biology, 2008, 13, 213-224.	2.6	96

#	Article	IF	CITATIONS
199	A Common Genetic Predisposition to Stress Sensitivity and Stress-Induced Nicotine Craving. Biological Psychiatry, 2008, 63, 164-171.	1.3	28
200	CB1Cannabinoid Receptor Modulates 3,4-Methylenedioxymethamphetamine Acute Responses and Reinforcement. Biological Psychiatry, 2008, 63, 1030-1038.	1.3	42
201	A2A adenosine receptor regulates glia proliferation and pain after peripheral nerve injury. Pain, 2008, 140, 95-103.	4.2	59
202	Interferon-Î <sup>3</sup> Is a Critical Modulator of CB <sub>2</sub> Cannabinoid Receptor Signaling during Neuropathic Pain. Journal of Neuroscience, 2008, 28, 12136-12145.	3.6	122
203	Crucial Role of CB <sub>2</sub> Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain. Journal of Neuroscience, 2008, 28, 12125-12135.	3.6	172
204	Interplay of β2* nicotinic receptors and dopamine pathways in the control of spontaneous locomotion. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15991-15996.	7.1	71
205	Chronic cocaine treatment alters dendritic arborization in the adult motor cortex through a CB1 cannabinoid receptor–dependent mechanism. Neuroscience, 2007, 146, 1536-1545.	2.3	25
206	Effects of constitutive deletion of opioid receptors on the basal densities of Fas and Fas-associated protein with death domain (FADD) in the mouse brain: A δ-opioid tone inhibits FADD. European Neuropsychopharmacology, 2007, 17, 366-374.	0.7	10
207	3,4-Methylenedioxymethamphetamine Self-Administration is Abolished in Serotonin Transporter Knockout Mice. Biological Psychiatry, 2007, 62, 669-679.	1.3	79
208	Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes. British Journal of Pharmacology, 2007, 150, 758-765.	5.4	18
209	Regulation of PI3K/Akt/CSK-3 pathway by cannabinoids in the brain. Journal of Neurochemistry, 2007, 102, 1105-1114.	3.9	193
210	CB <sub>1</sub> knockout mice display impaired functionality of 5â€HT <sub>1A</sub> and 5â€HT <sub>2A/C</sub> receptors. Journal of Neurochemistry, 2007, 103, 2111-2120.	3.9	73
211	MDMA attenuates THC withdrawal syndrome in mice. Psychopharmacology, 2007, 193, 75-84.	3.1	17
212	Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology, 2007, 195, 255-264.	3.1	35
213	Differential responses to anxiogenic drugs in a mouse model of panic disorder as revealed by Fos immunocytochemistry in specific areas of the fear circuitry. Amino Acids, 2007, 33, 677-688.	2.7	13
214	Attenuation of nicotine-induced rewarding effects in A2A knockout mice. Neuropharmacology, 2006, 51, 631-640.	4.1	50
215	Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology, 2006, 50, 111-122.	4.1	40
216	Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Neuropharmacology, 2006, 50, 123-132.	4.1	36

13

#	Article	IF	CITATIONS
217	Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology, 2006, 50, 788-806.	4.1	39
218	QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology, 2006, 51, 251-262.	4.1	26
219	Involvement of the endocannabinoid system in drug addiction. Trends in Neurosciences, 2006, 29, 225-232.	8.6	530
220	Opioid-induced Hyperalgesia in a Murine Model of Postoperative Pain. Anesthesiology, 2006, 104, 546-555.	2.5	128
221	Neuropathic pain is enhanced in δ-opioid receptor knockout mice. European Journal of Neuroscience, 2006, 23, 830-834.	2.6	105
222	Mu-opioid receptors are involved in the tolerance to nicotine antinociception. Journal of Neurochemistry, 2006, 97, 416-423.	3.9	55
223	Mu-opioid receptors are involved in the tolerance to nicotine antinociception. Journal of Neurochemistry, 2006, 98, 1343-1343.	3.9	1
224	A reliable model of intravenous MDMA self-administration in naÃ⁻ve mice. Psychopharmacology, 2006, 184, 212-220.	3.1	49
225	Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology, 2006, 184, 504-513.	3.1	82
226	Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiology of Disease, 2006, 24, 403-418.	4.4	50
227	The Lack of A2A Adenosine Receptors Diminishes the Reinforcing Efficacy of Cocaine. Neuropsychopharmacology, 2006, 31, 978-987.	5.4	79
228	Involvement of κ/Dynorphin System in WIN 55,212-2 Self-Administration in Mice. Neuropsychopharmacology, 2006, 31, 1957-1966.	5.4	61
229	B83 DEPRESSIVE-LIKE BEHAVIOURAL AND BIOCHEMICAL RESPONSES IN CB1 KNOCKOUT MICE. Behavioural Pharmacology, 2005, 16, S92.	1.7	0
230	B61 MDMA ATTENUATES THC WITHDRAWAL SYNDROME IN MICE. Behavioural Pharmacology, 2005, 16, S85.	1.7	0
231	B60 INVOLVEMENT OF OPIOID RECEPTORS IN THE TOLERANCE TO NICOTINE ANTINOCICEPTIVE EFFECTS. Behavioural Pharmacology, 2005, 16, S84-S85.	1.7	0
232	B57 INVOLVEMENT OF KAPPA/DYNORPHYN OPIOID SYSTEM IN CANNABINOID SELF-ADMINISTRATION IN MICE. Behavioural Pharmacology, 2005, 16, S83-S84.	1.7	0
233	κ- and δ-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1receptor knockout mice. European Journal of Neuroscience, 2005, 22, 2106-2110.	2.6	23
234	The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10. Nature Neuroscience, 2005, 8, 1735-1741.	14.8	48

#	Article	IF	CITATIONS
235	The role of the cannabinoid system in nicotine addiction. Pharmacology Biochemistry and Behavior, 2005, 81, 381-386.	2.9	63
236	Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology, 2005, 181, 260-269.	3.1	55
237	Lack of CB1 Cannabinoid Receptor Impairs Cocaine Self-Administration. Neuropsychopharmacology, 2005, 30, 1670-1680.	5.4	197
238	Nicotine-Induced Antinociception, Rewarding Effects, and Physical Dependence Are Decreased in Mice Lacking the Preproenkephalin Gene. Journal of Neuroscience, 2005, 25, 1103-1112.	3.6	133
239	Modulation of Anxiety-Like Behavior and Morphine Dependence in CREB-Deficient Mice. Neuropsychopharmacology, 2004, 29, 1122-1133.	5.4	107
240	The rewarding properties of MDMA are preserved in mice lacking u-opioid receptors. European Journal of Neuroscience, 2004, 20, 853-858.	2.6	47
241	Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. European Journal of Neuroscience, 2004, 20, 2203-2213.	2.6	74
242	Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neuroscience, 2004, 20, 2737-2748.	2.6	106
243	Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. British Journal of Pharmacology, 2004, 142, 1309-1317.	5.4	26
244	Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 338-349.	3.0	45
245	Prevention of fentanyl-induced delayed pronociceptive effects in mice lacking the protein kinase CÎ <sup>3</sup> gene. Neuropharmacology, 2004, 46, 264-272.	4.1	35
246	Neurofilament proteins and cAMP pathway in brains of μ-, Î- or κ-opioid receptor gene knock-out mice: effects of chronic morphine administration. Neuropharmacology, 2004, 46, 519-530.	4.1	27
247	Effects of nandrolone on acute morphine responses, tolerance and dependence in mice. European Journal of Pharmacology, 2003, 465, 69-81.	3.5	40
248	Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. European Journal of Neuroscience, 2003, 17, 155-159.	2.6	64
249	Increase of morphine withdrawal in mice lacking A <sub>2a</sub> receptors and no changes in CB <sub>1</sub> /A <sub>2a</sub> double knockout mice. European Journal of Neuroscience, 2003, 17, 315-324.	2.6	52
250	Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones. European Journal of Neuroscience, 2003, 17, 701-708.	2.6	84
251	Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. European Journal of Neuroscience, 2003, 17, 427-427.	2.6	0
252	Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice. European Journal of Neuroscience, 2003, 18, 2197-2202.	2.6	41

#	Article	IF	CITATIONS
253	Place Preference Test in Rodents. , 2003, Chapter 10, Unit 10.4.		6
254	Place Preference Test in Rodents. Current Protocols in Neuroscience, 2003, 22, Unit 9.15.	2.6	6
255	Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. European Neuropsychopharmacology, 2003, 13, 401-410.	0.7	53
256	Morphine withdrawal is modified in pituitary adenylate cyclase-activating polypeptide type I-receptor-deficient mice. Molecular Brain Research, 2003, 110, 109-118.	2.3	27
257	Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone. Pain, 2003, 104, 139-148.	4.2	42
258	Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology, 2002, 43, 857-867.	4.1	230
259	Knockout of ERK1 MAP Kinase Enhances Synaptic Plasticity in the Striatum and Facilitates Striatal-Mediated Learning and Memory. Neuron, 2002, 34, 807-820.	8.1	420
260	Cannabinoid Addiction: Behavioral Models and Neural Correlates. Journal of Neuroscience, 2002, 22, 3326-3331.	3.6	192
261	Motivational Effects of Cannabinoids Are Mediated by μ-Opioid and κ-Opioid Receptors. Journal of Neuroscience, 2002, 22, 1146-1154.	3.6	246
262	Attenuation of Nicotine-Induced Antinociception, Rewarding Effects, and Dependence in μ-Opioid Receptor Knock-Out Mice. Journal of Neuroscience, 2002, 22, 10935-10940.	3.6	213
263	Study of cannabinoid dependence in animals. , 2002, 95, 153-164.		129
264	Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology, 2002, 159, 379-387.	3.1	444
265	Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology, 2002, 163, 111-117.	3.1	205
266	Age-related changes of anandamide metabolism in CB1cannabinoid receptor knockout mice: correlation with behaviour. European Journal of Neuroscience, 2002, 15, 1178-1186.	2.6	137
267	Spontaneous network activity of cerebellar granule neurons: impairment byin vivochronic cannabinoid administration. European Journal of Neuroscience, 2002, 16, 641-651.	2.6	13
268	Behavioural and biochemical evidence for interactions between Δ9-tetrahydrocannabinol and nicotine. British Journal of Pharmacology, 2002, 135, 564-578.	5.4	270
269	Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Molecular Brain Research, 2001, 92, 78-84.	2.3	133
270	Impairment of Mossy Fiber Long-Term Potentiation and Associative Learning in Pituitary Adenylate Cyclase Activating Polypeptide Type I Receptor-Deficient Mice. Journal of Neuroscience, 2001, 21, 5520-5527.	3.6	167

#	Article	IF	CITATIONS
271	Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration. Journal of Neuroscience, 2001, 21, 5344-5350.	3.6	347
272	Absence of Δ-9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice. Journal of Neuroscience, 2001, 21, 9499-9505.	3.6	130
273	Δ9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activationin vivodepends on dopaminergic transmission. European Journal of Neuroscience, 2001, 14, 342-352.	2.6	144
274	Lack of dependence and rewarding effects of deltorphin II in muâ€opioid receptorâ€deficient mice. European Journal of Neuroscience, 2001, 13, 153-161.	2.6	15
275	Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene. British Journal of Pharmacology, 2001, 132, 1485-1492.	5.4	13
276	Lack of dependence and rewarding effects of deltorphin II in mu-opioid receptor-deficient mice. European Journal of Neuroscience, 2001, 13, 153-161.	2.6	22
277	Increased rewarding properties of morphine in dopamine-transporter knockout mice. European Journal of Neuroscience, 2000, 12, 1827-1837.	2.6	75
278	Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. European Journal of Neuroscience, 2000, 12, 4038-4046.	2.6	216
279	Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. European Journal of Neuroscience, 2000, 12, 1038-1046.	2.6	73
280	Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nature Genetics, 2000, 25, 195-200.	21.4	644
281	Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties. European Journal of Pharmacology, 2000, 401, 197-204.	3.5	10
282	A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice. Psychopharmacology, 2000, 147, 436-438.	3.1	201
283	Involvement of the Extracellular Signal-Regulated Kinase Cascade for Cocaine-Rewarding Properties. Journal of Neuroscience, 2000, 20, 8701-8709.	3.6	500
284	Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice. Journal of Neuroscience, 2000, 20, 9284-9289.	3.6	105
285	Altered emotional and locomotor responses in mice deficient in the transcription factor CREM. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14094-14099.	7.1	75
286	Effects of a delta opioid receptor agonist and inhibitors of enkephalin catabolism on periaqueductal gray neurons in the rat midbrain: Anin vitro study. Neurophysiology, 1999, 31, 316-322.	0.3	0
287	μ-Opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγS binding assays. European Journal of Pharmacology, 1999, 383, 209-214.	3.5	38
288	Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception. European Journal of Pharmacology, 1999, 383, 29-37.	3.5	7

#	Article	IF	CITATIONS
289	Disruption of the kappa -opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa -agonist U-50,488H and attenuates morphine withdrawal. EMBO Journal, 1998, 17, 886-897.	7.8	356
290	Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol. British Journal of Pharmacology, 1998, 125, 1567-1577.	5.4	166
291	Cerebral glucose metabolism during opioid withdrawal following methylnaloxonium injection into the locus coeruleus. Brain Research, 1998, 814, 1-12.	2.2	6
292	Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. European Journal of Pharmacology, 1998, 354, 1-7.	3.5	91
293	Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord. European Journal of Pharmacology, 1998, 356, 139-148.	3.5	3
294	Genetic analysis of drug addiction: the role of cAMP response element binding protein. Journal of Molecular Medicine, 1998, 76, 104-110.	3.9	96
295	Recent Findings on the Mechanism of Action of Morphine. CNS Drugs, 1998, 10, 1-10.	5.9	7
296	Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and) Tj ETQq0 0 0 rgBT /Ove 383-391.	rlock 10 Tr 4.2	f 50 467 Td ( 46
297	Physiological antagonism between endogenous CCK and opioid: Clinical perspectives in the management of pain. Behavioral and Brain Sciences, 1997, 20, 460-461.	0.7	0
298	Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature, 1997, 388, 586-589.	27.8	410
299	The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCK B receptor antagonist. Psychopharmacology, 1997, 131, 79-85.	3.1	55
300	CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology, 1997, 132, 227-236.	3.1	17
301	Participation of Noradrenergic Pathways in the Expression of Opiate Withdrawal: Biochemical and Pharmacological Evidence. Neuroscience and Biobehavioral Reviews, 1997, 21, 91-104.	6.1	187
302	Mécanisme d'action de la morphine. Medecine/Sciences, 1997, 13, 232.	0.2	0
303	Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. British Journal of Pharmacology, 1996, 119, 174-182.	5.4	20
304	Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids. European Journal of Pharmacology, 1996, 312, 15-25.	3.5	26
305	Reduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB. Science, 1996, 273, 657-659.	12.6	280
306	The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats. Psychopharmacology, 1996, 123, 119-126.	3.1	49

#	Article	IF	CITATIONS
307	Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene. Nature, 1996, 383, 819-823.	27.8	1,652
308	Protein Kinases in the Rat Nucleus Accumbens are Involved in the Aversive Component of Opiate Withdrawal. European Journal of Neuroscience, 1996, 8, 2671-2678.	2.6	34
309	Neuropsychopharmacology of Opiate Dependence. Neuroscience Intelligence Unit, 1996, , 77-124.	0.5	1
310	Treatment of Opiate Withdrawal. Neuroscience Intelligence Unit, 1996, , 153-179.	0.5	0
311	Neurophysiology of Opiate Dependence. Neuroscience Intelligence Unit, 1996, , 35-46.	0.5	0
312	Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology, 1995, 120, 400-408.	3.1	46
313	Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 565-75.	3.0	51
314	Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacology Biochemistry and Behavior, 1995, 52, 145-152.	2.9	110
315	Study of the mechanisms involved in behavioral changes induced by flunitrazepam in morphine withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 973-991.	4.8	9
316	Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist. European Journal of Pharmacology, 1995, 286, 79-93.	3.5	19
317	Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK <sub>B</sub> antagonist PDâ€∎34,308. British Journal of Pharmacology, 1995, 114, 1031-1039.	5.4	24
318	Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA. European Journal of Pharmacology, 1994, 268, 215-221.	2.6	83
319	Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacology Biochemistry and Behavior, 1994, 48, 363-369.	2.9	16
320	Attenuation of morphine withdrawal by injection of a protein kinase inhibitor into the locus coeruleus and the periaqueductal gray matter. Regulatory Peptides, 1994, 54, 175-176.	1.9	2
321	Antinociception induced by exogenous and endogenous opioids: Role of different brain structures. Regulatory Peptides, 1994, 54, 309-310.	1.9	0
322	CCK-B Antagonists Exhibit Antidepressant-Like Effects and Potentiate Endogenous Enkephalin Analgesia Annals of the New York Academy of Sciences, 1994, 713, 355-357.	3.8	8
323	Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 1073-1092.	4.8	79
324	Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain, 1994, 58, 77-83.	4.2	51

#	Article	IF	CITATIONS
325	D1 dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat. Pharmacology Biochemistry and Behavior, 1993, 45, 239-242.	2.9	145
326	Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Research, 1993, 622, 105-112.	2.2	60
327	Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Research, 1993, 605, 128-138.	2.2	145
328	Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neuroscience Letters, 1993, 160, 193-196.	2.1	31
329	RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neuroscience Letters, 1993, 156, 135-140.	2.1	40
330	Effect of mixed (RB 38A) and selective (RB 38B) inhibitors of enkephalin degrading enzymes on a model of depression in the rat. Biological Psychiatry, 1993, 34, 100-107.	1.3	42
331	Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. NeuroReport, 1993, 4, 947-950.	1.2	53
332	Neural substrates of opiate withdrawal. Trends in Neurosciences, 1992, 15, 186-191.	8.6	343
333	Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. Drug and Alcohol Dependence, 1992, 30, 293-300.	3.2	14
334	Mixed-inhibitor-prodrug as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. Journal of Medicinal Chemistry, 1992, 35, 2473-2481.	6.4	134
335	Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology, 1992, 31, 1231-1241.	4.1	113
336	Influence of different benzodiazepines on the experimental morphine abstinence syndrome. Psychopharmacology, 1991, 105, 197-203.	3.1	27
337	Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. Neuropharmacology, 1990, 29, 215-223.	4.1	31
338	Effects induced by chronic treatment with selective D <sub>1</sub> or D <sub>2</sub> antagonists on openâ€field behavior and colonic temperature. Fundamental and Clinical Pharmacology, 1990, 4, 341-356.	1.9	7
339	Differences in physical dependence induced by selective μ or δ opioid agonists and by endogenous enkephalins protected by peptidase inhibitors. Brain Research, 1990, 520, 247-254.	2.2	58
340	Comparative study in mice of flunitrazepam vs. diazepam on morphine withdrawal syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 927-933.	4.8	16
341	Clarity on Cannabinoid-Based Products in Medicine. European Medical Journal Neurology, 0, , .	0.0	1